The health care systems in Europe and the rest of the western world have come under a tremendous pressure to increase performance with regard to cost efficacy and treatment quality. Especially in the area of solid cancers patients and society experience escalating cost of novel therapies with only a marginal benefit on median survival. A prime reason for low efficacy in the cancer area is a huge heterogeneity in between patients. A high degree of responsiveness can however be obtained by identifying the right combination of existing drugs for the individual patient. Health authorities and patients therefore push to identify technologies that can match patient and treatment.
The ChemoGuide technology has the ability to provide a functional answer of how to match the individual patient with a efficacious treatment regimen.